MapLight Therapeutics, Inc. (MPLT) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
MPLT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 15, 2026, MapLight Therapeutics, Inc. (MPLT) trades at a price-to-earnings ratio of -15.4x, with a stock price of $28.73 and trailing twelve-month earnings per share of $-2.48.
Relative to the broader market, MPLT trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MPLT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MPLT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $539M | 14.5 | 1.31 | -3% | |
| $4B | 9.3 | - | +68% | |
| $2B | 6.7Lowest | 0.65Best | +817%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See MPLT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MPLT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare with Peers
Compare business quality, growth, and profitability against top sector peers.
Start ComparisonMPLT — Frequently Asked Questions
Quick answers to the most common questions about buying MPLT stock.
Is MPLT stock overvalued or undervalued?
MPLT current P/E: -15.4x. 5-year average P/E: N/A. Percentile: N/A.
How does MPLT's valuation compare to peers?
MapLight Therapeutics, Inc. P/E of -15.4x compares to sector median of N/A. Sector comparison provides relative valuation context.
What is MPLT's PEG ratio?
MPLT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.